Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy, safety, and pharmacokinetics of XEMBIFY plus standard medical treatment (SMT) versus placebo plus SMT to pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• Bacterial Infections
• Hypogammaglobulinemia
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• XEMBIFY (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Status: RECRUITING